Regulation of NADPH oxidase (Nox2) by lipid rafts in breast carcinoma cells

International Journal of Oncology

Volumn 37, Issue 6, 2010, Pages 1483-1493

  Malla, Rama Rao ^a   Raghu, Hari ^a   Rao, Jasti S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Lipid rafts and breast cancer; NADPH oxidase; ROS

Indexed keywords

CHOLESTEROL; GLYCOPROTEIN; GLYCOPROTEIN 91; GLYCOPROTEIN P22; METHYL BETA CYCLODEXTRIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CELL MEMBRANE; CELLULAR DISTRIBUTION; CHEMICAL ANALYSIS; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME REGULATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; LIPID RAFT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BETA-CYCLODEXTRINS; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE MICRODOMAINS; NADPH OXIDASE;

EID: 78649914892     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000801     Document Type: Article

References (53)

1. Kahan Z and Thurzo L: Breakthrough in breast cancer chemoprevention. Orv Hetil 144: 597-603, 2003.
2. Daudt A, Alberg AJ and Helzlsouer KJ: Epidemiology, prevention, and early detection of breast cancer. Curr Opin Oncol 8: 455-461, 1996. (Pubitemid 26405846)
3. McPherson K, Steel CM and Dixon JM: ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 321: 624-628, 2000.
4. Dai Q, Gao YT, Shu XO, Yang G, Milne G, Cai Q, Wen W, Rothman N, Cai H, Li H, Xiang Y, Chow WH and Zheng W: Oxidative stress, obesity, and breast cancer risk: results from the Shanghai Women's Health Study. J Clin Oncol 27: 2482-2488, 2009.
5. Sumimoto H, Ueno N, Yamasaki T, Taura M and Takeya R: Molecular mechanism underlying activation of superoxide-producing NADPH oxidases: roles for their regulatory proteins. Jpn J Infect Dis 57: S24-S25, 2004.
6. Gorlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F and Busse R: A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res 87: 26-32, 2000.
7. Dinauer MC, Pierce EA, Bruns GA, Curnutte JT and Orkin SH: Human neutrophil cytochrome b light chain (p22-phox). Gene structure, chromosomal location, and mutations in cytochrome-negative autosomal recessive chronic granulomatous disease. J Clin Invest 86: 1729-1737, 1990.
8. Nobuhisa I, Takeya R, Ogura K, Ueno N, Kohda D, Inagaki F and Sumimoto H: Activation of the superoxide-producing phagocyte NADPH oxidase requires co-operation between the tandem SH3 domains of p47phox in recognition of a polyproline type II helix and an adjacent alpha-helix of p22phox. Biochem J 396: 183-192, 2006.
9. Viedt C, Fei J, Krieger-Brauer HI, Brandes RP, Teupser D, Kamimura M, Katus HA and Kreuzer J: Role of p22phox in angiotensin II and platelet-derived growth factor AA induced activator protein 1 activation in vascular smooth muscle cells. J Mol Med 82: 31-38, 2004. (Pubitemid 38168100)
10. Jin S and Zhou F: Lipid raft redox signaling platforms in vascular dysfunction: features and mechanisms. Curr Atheroscler Rep 11: 220-226, 2009.
11. Shao D, Segal AW and Dekker LV: Lipid rafts determine efficiency of NADPH oxidase activation in neutrophils. FEBS Lett 550: 101-106, 2003. (Pubitemid 37281365)
12. Han W, Li H, Villar VA, Pascua AM, Dajani MI, Wang X, Natarajan A, Quinn MT, Felder RA, Jose PA and Yu P: Lipid rafts keep NADPH oxidase in the inactive state in human renal proximal tubule cells. Hypertension 51: 481-487, 2008.
13. Barman S and Nayak DP: Lipid raft disruption by cholesterol depletion enhances influenza A virus budding from MDCK cells. J Virol 81: 12169-12178, 2007.
14. Carter GC, Bernstone L, Sangani D, Bee JW, Harder T and James W: HIV entry in macrophages is dependent on intact lipid rafts. Virology 386: 192-202, 2009.
15. Ilangumaran S and Hoessli DC: Effects of cholesterol depletion by cyclodextrin on the sphingolipid microdomains of the plasma membrane. Biochem J 335 (Pt. 2): 433-440, 1998. (Pubitemid 28491081)
16. Zidovetzki R and Levitan I: Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. Biochim Biophys Acta 1768: 1311-1324, 2007. (Pubitemid 46782714)
17. Du W and Ayscough KR: Methyl beta-cyclodextrin reduces accumulation of reactive oxygen species and cell death in yeast. Free Radic Biol Med 46: 1478-1487, 2009.
18. Harder T, Scheiffele P, Verkade P and Simons K: Lipid domain structure of the plasma membrane revealed by patching of membrane components. J Cell Biol 141: 929-942, 1998.
19. Vilhardt F and van DB: The phagocyte NADPH oxidase depends on cholesterol-enriched membrane microdomains for assembly. EMBO J 23: 739-748, 2004.
20. Pralle A, Keller P, Florin EL, Simons K and Horber JK: Sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells. J Cell Biol 148: 997-1008, 2000.
21. Droge W: Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95, 2002.
22. 2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem J 418: 29-37, 2009.
23. Minakami R and Sumimotoa H: Phagocytosis-coupled activation of the superoxide-producing phagocyte oxidase, a member of the NADPH oxidase (nox) family. Int J Hematol 84: 193-198, 2006.
24. Yu L, Quinn MT, Cross AR and Dinauer MC: Gp91(phox) is the heme binding subunit of the superoxide-generating NADPH oxidase. Proc Natl Acad Sci USA 95: 7993-7998, 1998. (Pubitemid 128619134)
25. Sumimoto H, Miyano K and Takeya R: Molecular composition and regulation of the Nox family NAD(P)H oxidases. Biochem Biophys Res Commun 338: 677-686, 2005. (Pubitemid 41540615)
26. Sumimoto H, Kage Y, Nunoi H, Sasaki H, Nose T, Fukumaki Y, Ohno M, Minakami S and Takeshige K: Role of Src homology 3 domains in assembly and activation of the phagocyte NADPH oxidase. Proc Natl Acad Sci USA 91: 5345-5349, 1994.
27. Li YC, Park MJ, Ye SK, Kim CW and Kim YN: Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol 168: 1107-1118, 2006.
28. Marquez DC, Chen HW, Curran EM, Welshons WV and Pietras RJ: Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Mol Cell Endocrinol 246: 91-100, 2006.
29. Su Y, Vanderlaag K, Ireland C, Ortiz J, Grage H, Safe S and Frankel AE: 1,1-Bis(3′-indolyl)-1-(p-biphenyl)methane inhibits basal-like breast cancer growth in athymic nude mice. Breast Cancer Res 9: R56, 2007.
30. Rao PV, Maddala R, John F and Zigler JS Jr: Expression of nonphagocytic NADPH oxidase system in the ocular lens. Mol Vis 10: 112-121, 2004. (Pubitemid 38628969)
31. Ostrakhovitch EA and Li SS: NIP1/DUOXA1 expression in epithelial breast cancer cells: regulation of cell adhesion and actin dynamics. Breast Cancer Res Treat 119: 773-786, 2009.
32. Freeman MR and Solomon KR: Cholesterol and prostate cancer. J Cell Biochem 91: 54-69, 2004.
33. Duncan RE, El-Sohemy A and Archer MC: Dietary factors and the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase: implications for breast cancer and development. Mol Nutr Food Res 49: 93-100, 2005. (Pubitemid 40379809)
34. Duncan RE, El-Sohemy A and Archer MC: Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity. J Biol Chem 279: 33079-33084, 2004.
35. Sheets ED, Holowka D and Baird B: Critical role for cholesterol in Lyn-mediated tyrosine phosphorylation of FcepsilonRI and their association with detergent-resistant membranes. J Cell Biol 145: 877-887, 1999.
36. Dreja K, Voldstedlund M, Vinten J, Tranum-Jensen J, Hellstrand P and Sward K: Cholesterol depletion disrupts caveolae and differentially impairs agonist-induced arterial contraction. Arterioscler Thromb Vasc Biol 22: 1267-1272, 2002. (Pubitemid 34875735)
37. Smith RD, Babiychuk EB, Noble K, Draeger A and Wray S: Increased cholesterol decreases uterine activity: functional effects of cholesterol alteration in pregnant rat myometrium. Am J Physiol Cell Physiol 288: C982-C988, 2005.
38. Gould AL, Davies GM, Alemao E, Yin DD and Cook JR: Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clin Ther 29: 778-794, 2007.
39. Pfitzner I, Francz PI and Biesalski HK: Carotenoid:methyl-beta- cyclodextrin formulations: an improved method for supplementation of cultured cells. Biochim Biophys Acta 1474: 163-168, 2000.
40. Davalos A, de la PG, Sanchez-Martin CC, Teresa GM, Bartolome B and Lasuncion MA: Effects of red grape juice polyphenols in NADPH oxidase subunit expression in human neutrophils and mononuclear blood cells. Br J Nutr 1-11, 2009.
41. Murillo I and Henderson LM: Expression of gp91phox/Nox2 in COS-7 cells: cellular localization of the protein and the detection of outward proton currents. Biochem J 385: 649-657, 2005.
42. Gupte SA, Kaminski PM, Floyd B, Agarwal R, Ali N, Ahmad M, Edwards J and Wolin MS: Cytosolic NADPH may regulate differences in basal Nox oxidase-derived superoxide generation in bovine coronary and pulmonary arteries. Am J Physiol Heart Circ Physiol 288: H13-H21, 2005.
43. Archer SL, Reeve HL, Michelakis E, Puttagunta L, Waite R, Nelson DP, Dinauer MC and Weir EK: O2 sensing is preserved in mice lacking the gp91phox subunit of NADPH oxidase. Proc Natl Acad Sci USA 96: 7944-7949, 1999. (Pubitemid 29328387)
44. Li JM, Gall NP, Grieve DJ, Chen M and Shah AM: Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40: 477-484, 2002.
45. MacCarthy PA, Grieve DJ, Li JM, Dunster C, Kelly FJ and Shah AM: Impaired endothelial regulation of ventricular relaxation in cardiac hypertrophy: role of reactive oxygen species and NADPH oxidase. Circulation 104: 2967-2974, 2001. (Pubitemid 33139111)
46. Juhasz A, Ge Y, Markel S, Chiu A, Matsumoto L, van BJ, Roy K and Doroshow JH: Expression of NADPH oxidase homologues and accessory genes in human cancer cell lines, tumours and adjacent normal tissues. Free Radic Res 43: 523-532, 2009.
47. Kawahara T, Ritsick D, Cheng G and Lambeth JD: Point mutations in the proline-rich region of p22phox are dominant inhibitors of Nox1- and Nox2-dependent reactive oxygen generation. J Biol Chem 280: 31859-31869, 2005. (Pubitemid 41291936)
48. Allen JA, Halverson-Tamboli RA and Rasenick MM: Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci 8: 128-140, 2007.
49. London E and Brown DA: Insolubility of lipids in triton X-100: physical origin and relationship to sphingolipid/cholesterol membrane domains (rafts). Biochim Biophys Acta 1508: 182-195, 2000.
50. Scheel-Toellner D, Wang K, Singh R, Majeed S, Raza K, Curnow SJ, Salmon M and Lord JM: The death-inducing signalling complex is recruited to lipid rafts in Fas-induced apoptosis. Biochem Biophys Res Commun 297: 876-879, 2002.
51. Li H, Han W, Villar VA, Keever LB, Lu Q, Hopfer U, Quinn MT, Felder RA, Jose PA and Yu P: D1-like receptors regulate NADPH oxidase activity and subunit expression in lipid raft microdomains of renal proximal tubule cells. Hypertension 53: 1054-1061, 2009.
52. Zhang AY, Yi F, Zhang G, Gulbins E and Li PL: Lipid raft clustering and redox signaling platform formation in coronary arterial endothelial cells. Hypertension 47: 74-80, 2006.
53. Liu Y, Sun R, Wan W, Wang J, Oppenheim JJ, Chen L and Zhang N: The involvement of lipid rafts in epidermal growth factor-induced chemotaxis of breast cancer cells. Mol Membr Biol 24: 91-101, 2007.